These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 36147329)

  • 1. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.
    Hao X; Zhang Z; Ma J; Cheng L; Ji Y; Liu Y; Zhao D; Zhang W; Li C; Yan L; Margolis D; Zhu Q; Zhang Y; Zhang F
    Front Pharmacol; 2022; 13():983505. PubMed ID: 36147329
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
    J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
    Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
    Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
    Okada H; Ishikawa K; Itoh Y; Noda Y; Eto T; Pilla Reddy V; Chen CC; Gibbs M; Johnsson E
    J Infect Chemother; 2023 Nov; 29(11):1061-1067. PubMed ID: 37524201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.
    Schmidt P; Gong J; Narayan K; Gupta D; Engler F; Li Y; Copans A; Campanaro E
    Infect Dis Ther; 2023 May; 12(5):1365-1377. PubMed ID: 37185797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
    Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
    Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
    Meng X; Wang P; Xiong Y; Wu Y; Lin X; Lu S; Li R; Zhao B; Liu J; Zeng S; Zeng L; Wu Y; Lu Y; Zhang J; Liu D; Wang S; Lu H
    Emerg Microbes Infect; 2021 Dec; 10(1):1638-1648. PubMed ID: 34346827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Wu X; Li N; Wang G; Liu W; Yu J; Cao G; Wang J; Chen Y; Ma J; Wu J; Yang H; Mao X; He J; Yu Y; Qiu C; Li N; Yao S; Feng H; Yan J; Zhang W; Zhang J
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0035021. PubMed ID: 33972256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
    Li Y; Qi L; Bai H; Sun C; Xu S; Wang Y; Han C; Li Y; Liu L; Cheng X; Liu J; Lei C; Tong Y; Sun M; Yan L; Chen W; Liu X; Liu Q; Xie L; Wang X
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0106321. PubMed ID: 34491805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies.
    Moullan N; Asiago J; Stecco K; Hadi S; Albizem M; Tieu H; Hock B; Fenwick C; Lin K; Lengsfeld T; Poffenbarger L; Liu D; Trono D; Pantaleo G; Venkayya R; Bhuyan P
    Infect Dis Ther; 2024 Jan; 13(1):173-187. PubMed ID: 38221576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the combination of BRII-196/BRII-198 in the treatment of COVID-19 vaccine breakthrough infections.
    Guo XL; Wang K; Jin J; Dai LL
    Am J Transl Res; 2024; 16(3):916-924. PubMed ID: 38586111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.
    Shebley M; Wang S; Ali I; Krishnan P; Tripathi R; Reardon JM; Cafardi J; Rahav G; Caraco Y; Slim J; Al Akhrass F; Yu M; Hu Y; Ferreira RA; Alami NN
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01036. PubMed ID: 36537346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.
    Chen G; Zhang Y; Wu K; Jin T; Peng C; Jiang Q; Tian W; Chen Z; Shen Z; Sheng G
    BMC Infect Dis; 2023 Jun; 23(1):437. PubMed ID: 37370000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2.
    Zhang Q; Zhou R; Yang J; Dou C; Gan T; Liu F; Hu B; Song D; Lu C; Hu W
    Infect Dis Ther; 2022 Feb; 11(1):405-422. PubMed ID: 34878625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.